{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:04:05Z","timestamp":1793898245090,"version":"4.8.0"},"reference-count":64,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T00:00:00Z","timestamp":1683676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Phosphoinositide 3-kinase delta (PI3K\u03b4) plays key roles in normal B cell activation and is chronically activated in malignant B cells. Targeting of PI3K\u03b4 using FDA-approved drugs Idelalisib or Umbralisib has shown efficacy in treatment of multiple B cell malignancies. Duvelisib, an inhibitor targeting both PI3K\u03b4 and PI3K\u03b3 (PI3K\u03b4\u03b3i) has also been used for treatment of several leukemias and lymphomas and was suggested to offer potential additional benefits in supressing T cell and inflammatory responses. Transcriptomics analyses indicated that while most B cell subsets predominantly express PI3K\u03b4, plasma cells upregulate PI3K\u03b3. We thus assessed whether PI3K\u03b4\u03b3i treatment can impact chronic B cell activation in the context of an autoantibody-mediated disease. Using the TAPP1<jats:sup>R218L<\/jats:sup>xTAPP2<jats:sup>R211L<\/jats:sup> (TAPP KI) mouse model of lupus-like disease driven by dysregulated PI3K pathway activity, we performed 4 week PI3K\u03b4\u03b3i treatments and found significant reduction in CD86+ B cells, germinal center B cells, follicular helper T cells and plasma cells in multiple tissues. This treatment also significantly attenuated the abnormally elevated serum levels of IgG isotypes observed in this model. The profile of autoantibodies generated was markedly altered by PI3K\u03b4\u03b3i treatment, with significant reductions in IgM and IgG targeting nuclear antigens, matrix proteins and other autoantigens. Kidney pathology was also impacted, with reduced IgG deposition and glomerulonephritis. These results indicate that dual inhibition of PI3K\u03b4 and PI3K\u03b3 can target autoreactive B cells and may have therapeutic benefits in autoantibody-mediated disease.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1115244","type":"journal-article","created":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T19:16:41Z","timestamp":1683746201000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Dual inhibition of phosphoinositide 3-kinases delta and gamma reduces chronic B cell activation and autoantibody production in a mouse model of lupus"],"prefix":"10.3389","volume":"14","author":[{"given":"Folayemi","family":"Olayinka-Adefemi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sen","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron J.","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.07.029","article-title":"The PI3K pathway in human disease","volume":"170","author":"Fruman","year":"2017","journal-title":"Cell"},{"key":"B2","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1146\/annurev-immunol-032712-095946","article-title":"Signaling by the phosphoinositide 3-kinase family in immune cells","volume":"31","author":"Okkenhaug","year":"2013","journal-title":"Annu Rev Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.12027","article-title":"Rules of engagement: distinct functions for the four class I PI3K catalytic isoforms in immunity","volume":"1280","author":"Okkenhaug","year":"2013","journal-title":"Ann New York Acad Sci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1126\/science.1073560","article-title":"Impaired b and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice","volume":"297","author":"Okkenhaug","year":"2002","journal-title":"Science"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2006.12.007","article-title":"Antigen receptor signalling: a distinctive role for the p110delta isoform of PI3K","volume":"28","author":"Okkenhaug","year":"2007","journal-title":"Trends Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41577-022-00701-8","article-title":"The role of PI3K\u03b3 in the immune system: new insights and translational implications","volume":"22","author":"Lanahan","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0012-5","article-title":"Distinct roles for phosphoinositide 3-kinases \u03b3 and \u03b4 in malignant b cell migration","volume":"32","author":"Ali","year":"2018","journal-title":"Leukemia"},{"key":"B8","volume-title":"Systemic lupus erythematosus. in: StatPearls","author":"Justiz Vaillant","year":"2022"},{"key":"B9","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s11926-017-0707-z","article-title":"B cell-based treatments in SLE: past experience and current directions","volume":"19","author":"Liossis","year":"2017","journal-title":"Curr Rheumatol Rep"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102469","article-title":"Immunosuppressive\/Autoimmune disorders","volume":"53","author":"Richard-Eaglin","year":"2018","journal-title":"Nurs Clin North Am"},{"key":"B11","doi-asserted-by":"publisher","first-page":"102469","DOI":"10.1002\/jcla.20248","article-title":"Understanding the immunopathogenesis of autoimmune diseases by animal studies using gene modulation: a comprehensive review","volume":"19","author":"Lee","year":"2020","journal-title":"Autoimmun Rev"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2012.02.001","article-title":"Anti-histones antibodies in systemic lupus erythematosus: prevalence and frequency in neuropsychiatric lupus","volume":"22","author":"Sun","year":"2008","journal-title":"J Clin Lab Anal"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2012.02.001","article-title":"Updated assessment of the prevalence, spectrum and case definition of autoimmune disease","volume":"11","author":"Hayter","year":"2012","journal-title":"Autoimmun Rev"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1177\/09612033211028653","article-title":"10 years of belimumab experience: what have we learnt","volume":"30","author":"Levy","year":"2021","journal-title":"Lupus"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01604-z","article-title":"Anifrolumab: first approval","volume":"81","author":"Deeks","year":"2021","journal-title":"Drugs"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2009.08.026","article-title":"Suppression of phosphatidylinositol 3,4,5-trisphosphate production is a key determinant of b cell anergy","volume":"31","author":"Browne","year":"2009","journal-title":"Immunity"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-05205-1","article-title":"Systemic lupus erythematosus in a girl with PTEN variant and transaldolase deficiency: a novel phenotype","volume":"39","author":"Al-Mayouf","year":"2020","journal-title":"Clin Rheumatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20150537","article-title":"Continuous inhibitory signaling by both SHP-1 and SHIP-1 pathways is required to maintain unresponsiveness of anergic b cells","volume":"213","author":"Getahun","year":"2016","journal-title":"J Exp Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1801394","article-title":"A precision b cell-targeted therapeutic approach to autoimmunity caused by phosphatidylinositol 3-kinase pathway dysregulation","volume":"202","author":"Franks","year":"2019","journal-title":"J Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1042\/BST20150248","article-title":"Emerging evidence of signalling roles for PI(3,4)P2 in class I and II PI3K-regulated pathways","volume":"44","author":"Hawkins","year":"2016","journal-title":"Biochem Soc Trans"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2015.05.013","article-title":"Phosphatidylinositol (3,4) bisphosphate-specific phosphatases and effector proteins: a distinct branch of PI3K signaling","volume":"27","author":"Li","year":"2015","journal-title":"Cell Signalling"},{"key":"B22","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1042\/bj3510019","article-title":"Identification of pleckstrin-homology-domain-containing proteins with novel phosphoinositide-binding specificities","volume":"351","author":"Dowler","year":"2000","journal-title":"Biochem J"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.22.15.5479-5491.2002","article-title":"TAPP1 and TAPP2 are targets of phosphatidylinositol 3-kinase signaling in b cells: sustained plasma membrane recruitment triggered by the b-cell antigen receptor","volume":"22","author":"Marshall","year":"2002","journal-title":"Mol Cell Biol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201242371","article-title":"Interaction of TAPP adapter proteins with phosphatidylinositol (3,4)-bisphosphate regulates b-cell activation and autoantibody production","volume":"42","author":"Landego","year":"2012","journal-title":"Eur J Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1701440","article-title":"TAPP adaptors control b cell metabolism by modulating the phosphatidylinositol 3-kinase signaling pathway: a novel regulatory circuit preventing autoimmunity","volume":"201","author":"Jayachandran","year":"2018","journal-title":"J Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12943-019-0954-x","article-title":"Targeting PI3K in cancer: mechanisms and advances in clinical trials","volume":"18","author":"Yang","year":"2019","journal-title":"Mol Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.105","article-title":"The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K\/AKT\/S6 pathway and promotes apoptosis in CLL","volume":"29","author":"Balakrishnan","year":"2015","journal-title":"Leukemia"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-786566","article-title":"Duvelisib, a novel oral dual inhibitor of PI3K-\u03b4,\u03b3, is clinically active in advanced hematologic malignancies","volume":"131","author":"Flinn","year":"2018","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-05-850461","article-title":"The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL\/SLL","volume":"132","author":"Flinn","year":"2018","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S189032","article-title":"Oral PI3K-\u03b4,\u03b3 inhibitor for the management of people with chronic lymphocytic leukemia and small lymphocytic lymphoma: a narrative review on duvelisib","volume":"14","author":"Shah","year":"2021","journal-title":"Onco Targets Ther"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-07-587279","article-title":"IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells","volume":"124","author":"Dong","year":"2014","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2013.09.017","article-title":"PI3K-\u03b4 and PI3K-\u03b3 inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models","volume":"20","author":"Winkler","year":"2013","journal-title":"Chem Biol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.113.205955","article-title":"Novel phosphoinositide 3-kinase \u03b4,\u03b3 inhibitor: potent anti-inflammatory effects and joint protection in models of rheumatoid arthritis","volume":"348","author":"Boyle","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200838266","article-title":"Role of PI3K\u03b4 and PI3K\u03b3 in inflammatory arthritis and tissue localization of neutrophils","volume":"38","author":"Randis","year":"2008","journal-title":"Eur J Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20102012","article-title":"Role of TAPP1 and TAPP2 adaptor binding to PtdIns(3,4)P2 in regulating insulin sensitivity defined by knock-in analysis","volume":"434","author":"Wullschleger","year":"2011","journal-title":"Biochem J"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/nri2637","article-title":"Immunological genome project consortium. the immunological genome project: networks of gene expression in immune cells","volume":"9","author":"Heng","year":"2008","journal-title":"Nat Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12860","article-title":"Dysregulation of germinal centres in autoimmune disease","volume":"9","author":"Vinuesa","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1182\/blood-2008-02-078071","article-title":"T Follicular helper cells in germinal center b cell selection and lymphomagenesis","volume":"296","author":"Mintz","year":"2020","journal-title":"Immunol Rev"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2015.10.001","article-title":"B lymphocytes: how they develop and function","volume":"112","author":"LeBien","year":"2008","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/nri.2017.24","article-title":"BCR and co-receptor crosstalk facilitate the positive selection of self-reactive transitional b cells","volume":"37","author":"Metzler","year":"2015","journal-title":"Curr Opin Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00401","article-title":"Altered b cell signalling in autoimmunity","volume":"17","author":"Rawlings","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02061","article-title":"Lyn, Lupus, and (B) lymphocytes, a lesson on the critical balance of kinase signaling in immunity","volume":"9","author":"Brodie","year":"2018","journal-title":"Front Immunol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1002\/eji.201646596","article-title":"The complex association of Fc\u03b3RIIb with autoimmune susceptibility","volume":"10","author":"Verbeek","year":"2019","journal-title":"Front Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1126\/science.285.5436.2122","article-title":"B-cell-intrinsic function of TAPP adaptors in controlling germinal center responses and autoantibody production in mice","volume":"47","author":"Jayachandran","year":"2017","journal-title":"Eur J Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/383263a0","article-title":"Impaired fas response and autoimmunity in pten+\/- mice","volume":"285","author":"Di Cristofano","year":"1999","journal-title":"Science"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/ni1151","article-title":"Role of the inositol phosphatase SHIP in negative regulation of the immune system by the receptor Fc(gamma)RIIB","volume":"383","author":"Ono","year":"1996","journal-title":"Nature"},{"key":"B47","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1126\/scitranslmed.3009131","article-title":"The inhibitory fcgamma receptor modulates autoimmunity by limiting the accumulation of immunoglobulin g+ anti-DNA plasma cells","volume":"6","author":"Fukuyama","year":"2005","journal-title":"Nat Immunol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"246ra99","DOI":"10.1038\/s41590-018-0182-3","article-title":"Defective PTEN regulation contributes to b cell hyperresponsiveness in systemic lupus erythematosus","volume":"6","author":"Wu","year":"2014","journal-title":"Sci Transl Med"},{"key":"B49","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1038\/s41573-021-00209-1","article-title":"Hyperactivated PI3K\u03b4 promotes self and commensal reactivity at the expense of optimal humoral immunity","volume":"19","author":"Preite","year":"2018","journal-title":"Nat Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1001730","article-title":"PI3K inhibitors are finally coming of age","volume":"20","author":"Vanhaesebroeck","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1001730","article-title":"Phosphoinositide 3-kinase activity in T cells regulates the magnitude of the germinal center reaction","volume":"185","author":"Rolf","year":"2010","journal-title":"J Immunol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s10753-014-9818-0","article-title":"Regulation of T cell alloimmunity by PI3K\u03b3 and PI3K\u03b4","volume":"8","author":"Uehara","year":"2017","journal-title":"Nat Commun"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/nm1291","article-title":"Inhibition of PI3K\u03b4 improves systemic lupus in mice","volume":"37","author":"Wang","year":"2014","journal-title":"Inflammation"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00233","article-title":"PI3Kgamma inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus","volume":"11","author":"Barber","year":"2005","journal-title":"Nat Med"},{"key":"B55","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1073\/pnas.1004594107","article-title":"Characterization of novel PI3K\u03b4 inhibitors as potential therapeutics for SLE and lupus nephritis in pre-clinical studies","volume":"5","author":"Haselmayer","year":"2014","journal-title":"Front Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2015.05.017","article-title":"The bruton tyrosine kinase inhibitor PCI-32765 blocks b-cell activation and is efficacious in models of autoimmune disease and b-cell malignancy","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"B57","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/bjh.18053","article-title":"PI3K inhibitors in inflammation, autoimmunity and cancer","volume":"23","author":"Stark","year":"2015","journal-title":"Curr Opin Pharmacol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.281266","article-title":"Idelalisib reduces regulatory T cells and activates T helper 17 cell differentiation in relapsed refractory patients with chronic lymphocytic leukaemia","volume":"197","author":"Gadi","year":"2022","journal-title":"Br J Haematol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.281266","article-title":"PI3K inhibitors in chronic lymphocytic leukemia: where do we go from here","volume":"108","author":"Sk\u00e5nland","year":"2023","journal-title":"Haematologica"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01441-9","article-title":"Final results of a randomized, phase III study of rituximab with or without idelalisib followed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia","volume":"37","author":"Sharman","year":"2019","journal-title":"J Clin Oncol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2000043","article-title":"A T cell inflammatory phenotype is associated with autoimmune toxicity of the PI3K inhibitor duvelisib in chronic lymphocytic leukemia","volume":"36","author":"Gadi","year":"2022","journal-title":"Leukemia"},{"key":"B62","doi-asserted-by":"publisher","first-page":"78","DOI":"10.4049\/jimmunol.2000043","article-title":"Loss of phosphatidylinositol 3-kinase activity in regulatory T cells leads to neuronal inflammation","volume":"205","author":"Stark","year":"2020","journal-title":"J Immunol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/nature19834","article-title":"The PI3K p110\u03b4 isoform inhibitor idelalisib preferentially inhibits human regulatory T cell function","volume":"202","author":"Chellappa","year":"2019","journal-title":"JI"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.cnur.2018.04.002","article-title":"PI3K\u03b3 is a molecular switch that controls immune suppression","volume":"539","author":"Kaneda","year":"2016","journal-title":"Nature"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1115244\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T19:16:45Z","timestamp":1683746205000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1115244\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,10]]},"references-count":64,"alternative-id":["10.3389\/fimmu.2023.1115244"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1115244","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,10]]},"article-number":"1115244"}}